Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.

You May Also Be Interested In

• Black Hills Corp. (BKH) 3500 contracts of October 80 calls active, share price up 2.5%
• Micron Technology (MU) call put ratio 1.6 calls to 1 put amid share price up 1.5%
• Canadian Natural Resources (CNQ) 10600 contracts of January 57.50 calls trade